SCHEMBL4155284

SCHEMBL4155284

O=C(O)CCCc1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)N(CCO)CCO)cc3c12

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.38
POLB P06746 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 10/20 0.36
ALDH1A1 P00352 6/20 0.36
GAA P10253 3/20 0.36
HSD17B10 Q99714 4/20 0.36
HPGD P15428 3/20 0.36
USP2 O75604 1/20 0.36
KMT2A Q03164 2/20 0.35
VCAM1 P19320 1/20 0.35
MAPK1 P28482 1/20 0.34
NPC1 O15118 1/20 0.34
MEN1 O00255 1/20 0.34
HTT P42858 1/20 0.34
TP53 P04637 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4162646 0.92 KDM4E (0.35) RXFP1POLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL4155199 0.89 TP53 (0.37) RXFP1POLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL4155240 0.88 KDM4E (0.35) RXFP1POLBKDM4EALDH1A1GAA
SCHEMBL4163996 0.85 GAA (0.46) RXFP1KDM4EALDH1A1GAAHSD17B10
SCHEMBL4169887 0.85 KDM4E (0.55) RXFP1POLBKDM4EALDH1A1GAA
SCHEMBL4160571 0.83 GAA (0.44) RXFP1KDM4EALDH1A1GAAHSD17B10
SCHEMBL4156381 0.83 GAA (0.44) RXFP1POLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL4157685 0.83 KDM4E (0.48) RXFP1POLBKDM4EALDH1A1GAA
SCHEMBL4166910 0.83 KDM4E (0.39) RXFP1KDM4EALDH1A1GAAHSD17B10
Hydrochloric Acid SCHEMBL4164011 0.83 GAA (0.43) RXFP1POLBSMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 RXFP1 3999/4885POLB 1007/4885SMN1; SMN2 2559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.